N-of-One Secures $7 Million in Series B financing

The financing will be used to expand the company's leading precision medicine decision support solutions in oncology.

“This financing round marks a new and exciting chapter for N-of-One, and we are pleased to partner with Providence Ventures and Excel Venture Management to take the next step in solving the growing complexity of precision medicine. We look forward to collaborating with our lab and health system clients to incorporate clinical data along with the patient’s molecular profile to provide further refinement of treatment options. This is particularly important given the growing complexity of clinical trial eligibility criteria,” said Chris Cournoyer, CEO of N-of-One.

“Cancer treatment is not one size fits all, and finding the right treatment, to include appropriate clinical trials, as quickly as possible, is a top priority,” said Thomas Brown, executive director of the Swedish Cancer Institute and co-chair of Providence Health & Services’ Personalized Medicine Program. “We are thrilled to be expanding our relationship with N-of-One to scale molecular oncology decision making, bringing the promise of precision medicine to thousands of cancer patients.”

“We are delighted to be investors in N-of-One with its unrivaled technology for assisting physicians in determining the optimal treatment for their cancer patients in this era of personalized medicine,” commented board member Steve Gullans of Excel.